In LUAD, METTL7B is a potential therapeutic target for reversing gefitinib- and osimertinib-resistance by promoting three key reactive oxygen species scavengers (ROS) (87, 88).The dysregulation of the FTO-m6A axis in leukemia cells is required for EGFR-TKI (tyrosine kinase inhibitors) resistance, which can be prevented or eradicated by specifically targeting FTO (89). This evidence concerns the gene FTO and leukemia.